Bliss GVS Pharma Limited has announced that its Board of Directors, in a meeting held on May 23, 2026, took note of a Public Announcement regarding the execution of a Share Purchase Agreement (“SPA”) dated May 23, 2026. Under this agreement, certain existing shareholders—comprising promoters Mr. Narsimha Shibroor Kamath, Dr. Vibha Gagan Sharma, and Ms. Shruti Vishal Rao, along with public/non-promoter shareholders Mr. Gautam Rasiklal Ashra, Mr. Arjun Gautam Ashra, and M/s. Gulbarga Trading and Investment Private Limited—have agreed to transfer up to 43.30% of the total paid-up equity share capital of the company to Anupam Rasayan India Limited, the Purchaser. The transaction, which will lead to a change in shareholding and/or control, has triggered a mandatory open offer by the Purchaser to acquire up to 26% of the company’s total paid-up equity share capital on a fully diluted basis.

Bliss GVS Pharma Limited is a pharmaceutical company incorporated in 1984, headquartered in Mumbai, and engaged in the manufacturing, marketing, trading, and export of pharmaceutical formulations including suppositories, pessaries, capsules, tablets, and syrups. The company specializes in therapeutic areas such as anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, and contraceptive treatments, operating cGMP-compliant manufacturing plants. In 2026, the company has maintained a focus on its global market presence, with its portfolio including over 150 brands such as P-Alaxin, Lonart, Funbact, and Lofnac.

Regarding the financial results for the quarter ended March 2026 (Q4 FY 2025-26), the company reported a total income of ₹268.15 crores, representing a 13.3% increase quarter-on-quarter (QoQ) and a 27.7% increase year-on-year (YoY). The profit after tax for the same period stood at ₹37.00 crores, marking a 49.3% increase QoQ and a 122.2% increase YoY.